Literature DB >> 17079665

Adenosine A2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation.

Qing-Yuan Huang1, Catherine Wei, Liqun Yu, Joana E Coelho, Hai-Ying Shen, Anti Kalda, Joel Linden, Jiang-Fan Chen.   

Abstract

Endogenous adenosine acting at the adenosine A2A receptor (A2AR) can modify brain injury in a variety of neurological disorder models. However, both A2AR activation and inactivation have been shown to be neuroprotective in different situations, raising the intriguing possibility that A2ARs in distinct cellular elements may have different and even opposing effects. In this study, we developed three novel transgenic models to dissect out cell-type-specific actions of A2ARs on striatal damage by the mitochondrial toxin 3-nitropropionic acid (3-NP). Whereas global inactivation of A2ARs exacerbated 3-NP-induced neurological deficit behaviors and striatal damage, selective inactivation of A2ARs in forebrain neurons (using the Cre/loxP strategy) did not affect neurological deficit or striatal damage after the acute systemic treatment of 3-NP and intrastriatal injection of malonate. However, selective inactivation of A2ARs in bone marrow-derived cells (BMDCs) by transplanting bone marrow cells from global A2AR knock-out (KO) mice into wild-type C57BL/6 mice produced a similar phenotype of global A2AR KO mice, i.e., exacerbation of 3-NP-induced striatal damage. Thus, cell-type-selective inactivation of A2ARs reveals that A2ARs in BMDCs but not in forebrain neurons are an important contributor to striatal damage induced by mitochondrial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079665      PMCID: PMC6674538          DOI: 10.1523/JNEUROSCI.1907-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  14 in total

1.  CREB is a key regulator of striatal vulnerability in chemical and genetic models of Huntington's disease.

Authors:  Yun-Sik Choi; Boyoung Lee; Hee-Yeon Cho; Iza B Reyes; Xin-An Pu; Takaomi C Saido; Kari R Hoyt; Karl Obrietan
Journal:  Neurobiol Dis       Date:  2009-07-24       Impact factor: 5.996

Review 2.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 3.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

4.  Caffeine preferentially protects against oxygen-induced retinopathy.

Authors:  Shuya Zhang; Rong Zhou; Bo Li; Haiyan Li; Yanyan Wang; Xuejiao Gu; Lingyun Tang; Cun Wang; Dingjuan Zhong; Yuanyuan Ge; Yuqing Huo; Jing Lin; Xiao-Ling Liu; Jiang-Fan Chen
Journal:  FASEB J       Date:  2017-04-18       Impact factor: 5.191

5.  Genetic inactivation of the adenosine A2A receptor attenuates pathologic but not developmental angiogenesis in the mouse retina.

Authors:  Xiao-Ling Liu; Rong Zhou; Qi-Qi Pan; Xiao-Lin Jia; Wei-Na Gao; Jun Wu; Jing Lin; Jiang-Fan Chen
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-07       Impact factor: 4.799

Review 6.  Pathophysiological roles for purines: adenosine, caffeine and urate.

Authors:  Micaela Morelli; Anna R Carta; Anil Kachroo; Michael A Schwarzschild
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 7.  Adenosine receptors and epilepsy: current evidence and future potential.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin
Journal:  Int Rev Neurobiol       Date:  2014       Impact factor: 3.230

Review 8.  Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.

Authors:  Rodrigo A Cunha; Sergi Ferré; Jean-Marie Vaugeois; Jiang-Fan Chen
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

9.  Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.

Authors:  Anna R Carta; Anil Kachroo; Nicoletta Schintu; Kui Xu; Michael A Schwarzschild; Jadwiga Wardas; Micaela Morelli
Journal:  J Neurochem       Date:  2009-10-08       Impact factor: 5.372

10.  Neuronal adenosine A2A receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease.

Authors:  Maria Rosaria Domenici; Valentina Chiodi; Mirko Averna; Monica Armida; Antonella Pèzzola; Rita Pepponi; Antonella Ferrante; Michael Bader; Kjell Fuxe; Patrizia Popoli
Journal:  Purinergic Signal       Date:  2018-05-16       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.